Key terms
About AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AMGN news
Today
12:25am ET
BMO Capital Reaffirms Their Buy Rating on Amgen (AMGN)
Yesterday
11:34am ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN)
Yesterday
8:08am ET
Oppenheimer Remains a Buy on Amgen (AMGN)
Yesterday
8:06am ET
Amgen (AMGN) Receives a Buy from Piper Sandler
Yesterday
7:45am ET
AMGN Earnings: Amgen Surges After Raised Forecast, Weight Loss Drug Update
Yesterday
7:07am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
Yesterday
6:47am ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)
Yesterday
6:43am ET
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
May 02
4:05pm ET
Arrowhead earns $50M milestone from Royalty Pharma
May 02
4:03pm ET
Amgen narrows FY24 adjusted EPS view to $19.00-$20.20 from $18.90-$20.30
May 02
4:01pm ET
Amgen reports Q1 adjusted EPS $3.96, consensus $3.87
May 02
1:49pm ET
Notable companies reporting after market close
May 02
7:05am ET
Options Volatility and Implied Earnings Moves Today, May 02, 2024
May 01
9:20am ET
BMO sees CytomX rallying after ‘surprise’ data announcement
Apr 30
8:01am ET
Analysts’ Top Healthcare Picks: Laboratory (LH), Amgen (AMGN)
Apr 30
7:56am ET
Amgen settlement with Sandoz a positive, says Jefferies
Apr 30
7:21am ET
Amgen (AMGN) Gets a Buy from Truist Financial
Apr 30
5:37am ET
Sandoz, Amgen to resolve all patent disputes relating to denosumab biosimilars
Apr 26
9:02am ET
Amgen announces imminent submission of MAA to EMA for teprotumumab
Apr 24
6:30am ET
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO)
Apr 22
8:27am ET
Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN)
Apr 18
12:29am ET
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
Apr 17
5:45am ET
Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued
Apr 17
3:25am ET
Barclays Keeps Their Sell Rating on Amgen (AMGN)
Apr 16
5:28pm ET
Amgen to present Tezspire Phase 2a COPD data at ATS 2024
Apr 15
8:01am ET
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
Apr 15
7:40am ET
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)
Apr 15
7:22am ET
Amgen price target lowered to $360 from $370 at TD Cowen
Apr 11
9:56am ET
Early notable gainers among liquid option names on April 11th
Apr 03
7:00am ET
Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI)
Mar 25
8:01am ET
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Amgen (AMGN) and Petiq (PETQ)
No recent press releases are available for AMGN
AMGN Financials
Key terms
Ad Feedback
AMGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AMGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
